An in-person event, Pharmabiotics 2022, brought together individuals from academia and industry in the microbiome field to focus on how microbiome-based drug products will become a therapeutic reality in Europe. […]
Companies are now targeting the gut microbiome with therapies for fatty liver disease, hepatic encephalopathy, and more.. The liver is an incredibly complex organ—and its functioning leaves very little room […]
A virtual event held earlier this year, Microbiome Movement – Drug Development Europe 2022, provided a chance to bring together the microbiome drug development community to share updates and discuss […]
Of all the diseases and conditions linked to the gut microbiome, the inflammatory bowel diseases (IBDs) ulcerative colitis and Crohn’s disease have been some of the most promising indications for […]
Lyon- France – le 20 janvier 2022 – Créée en mars 2021, APM, qui compte 22 membres, est le fruit de l’union d’acteurs publics et privés engagés dans la promotion […]
Of all the respiratory diseases, one of them – COVID-19 – has been the focus of most of the research and attention over the past two years. While surely justified, […]
Many colleagues in the microbiome industry were able to gather in person once again for Global Engage’s 9thMicrobiome R&D and Business Collaboration Forum: Europe. The event had a wide-ranging program […]
Microbiome oncology company turns to world-leading CDMO to handle the challenges of manufacturing and scale-up Microbiome-focused oncology drug company everImmune, a spin-out from France’s top cancer research center, has signed […]
In medicine, the digestive tract (or ‘gut’) and the brain have long been treated as two separate entities – but research from the past few decades has discovered strong interconnections […]
At Pharmabiotics 2021 Conference & Partnering, Adrien Nivoliez, Biose Industrie CEO, held an Interactive Roundtable Discussion called Microbiome Therapeutics – the investment cycle from discovery to commercialization. Nivoliez spoke with […]